Kadmon Hlds

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). The company also provides various services and programs to support patients, prescribers, and pharmacies, including patient assistance programs to provide free medication to patients with limited or no insurance coverage; temporary shipments for patients on current or recent therapy; and nurse support services. In addition, it develops medicines in oncology, infectious diseases, immunology, and neurodegenerative diseases.  The company was formerly known as Kadmon Holdings. Kadmon Corporation was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; and Boston, Massachusetts.

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

Biogen

BioNTech SE

CRISPR Therapeutics

Editas Medicine

Illumina

Moderna

Pfizer

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

Los Angeles, California--(Newsfile Corp. - April 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ("Kadmon" or "the Company") (NASDAQ: KDMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 1, 2020 and March 10, 2021, inclusive...

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Kadmon Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, April 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ("Kadmon" or "the Company") (NASDAQ: KDMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 1, 2020 and March 10, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 2, 2021.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Kadmon Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SAN DIEGO & LORDSTOWN, Ohio--(BUSINESS WIRE)---- $KDMN #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Kadmon Holdings, Inc. (NASDAQ: KDMN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 1, 2020 and March 10, 2021. Kadmon is a biopharmaceutical company that develops small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Kadmon's

SHAREHOLDER ALERT: Robbins LLP Announces That Kadmon Holdings, Inc. (KDMN) is Being Sued for Misleading Shareholders

Atlanta, Georgia--(Newsfile Corp. - April 5, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Kadmon Holdings Inc. (NASDAQ: KDMN) ("Kadmon" or the "Company") securities between October 1, 2020 and March 10, 2021, inclusive (the "Class Period"). The complaint seeks to recover damages for alleged violations of the federal securities laws. If you purchased shares of Kadmon between October...

SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of Kadmon Holdings Inc. Investors and Encourages Investors With Significant Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and March 10, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2021. SO WHAT: If you purchased Kadmon securities during the Class Period you

KDMN BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Kadmon Holdings, Inc. Investors to Secure Counsel Before Important Deadline – KDMN

NEW YORK, April 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-01797, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired  Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action against Kadmon Holdings, Inc., and Certain Officers - KDMN

NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID).

Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place virtually April 10 - 15, 2021. KD033 is currently being evaluated in an ongoing Phase 1 study in patients with metastatic or locally advanced solid tumors.

Kadmon Announces Trial-In-Progress Poster on KD033 at the 2021 American Association for Cancer Research Annual Meeting

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.The investigation concerns whether Kadmon Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kadmon Holdings, Inc. - KDMN

The FDA has extended the review period for Kadmon Holdings Inc's (NASDAQ: KDMN) marketing application seeking approval for belumosudil to treat chronic graft-versus-host disease (cGVHD). The goal date for the Priority Review of belumosudil has been extended to August 30, from May 30.

Decision On Kadmon's Belumosudil US Application In Chronic GVHD Pushed Back By Three Months

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD). In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of belumosudil has been extended to August 30, 2021.

Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 37.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Kadmon Holdings, Inc. (KDMN) Reports Q4 Loss, Tops Revenue Estimates

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020. "With the acceptance of Kadmon's new drug application for belumosudil in cGVHD in hand, we are preparing for our potential commercial launch in light of our May 30th PDUFA date," said Harlan W.

Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates.

Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

MeiraGTx Holdings plc

NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) a subsidiary of Sino Biopharmaceutical Limited...

Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide

Kadmon's cGVHD asset is Belumosudil. The molecule has shown a strong efficacy profile.

Kadmon Looks Highly Investable Before PDUFA

Plains All American Pipeline

Catalyst Biosciences

Resonant

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks to Buy Now Trading Under $10 With Plenty of Upside Potential

Steven Cohen ( Trades , Portfolio ) has revealed a large addition to his stake in Kadmon Holdings Inc. (NASDAQ:KDMN) according to GuruFocus' Real-Time Picks, a Premium feature.

Steven Cohen Boosts Kadmon Holdings Stake

The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.

Why Kadmon Stock Popped Today

Bristol-Myers

Protagonist Therapeutics

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Corcept Therapeutics

Dynavax Technologies

G1 Therapeutics

ImmunoGen

Supernus Pharmaceuticals

Vertex Pharmaceuticals

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

7 Great Biotech Stocks to Buy and Hold Now

IAMGOLD

Infinera

Plug Power

Silvercorp Metals

United Microelectronics

In times of market turbulence, cheap stocks offer a unique way to escape the broad moves up and down and instead benefit from big potential.
The post 7 Cheap Stocks to Buy With Great Potential appeared first on InvestorPlace.

7 Cheap Stocks to Buy With Great Potential

The company reported positive results from a clinical trial for one of its most promising pipeline candidates.

Why Kadmon Holdings Jumped Today

Atara Biotherapeutics

Homology Medicines

Viking Therapeutics

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

News for Kadmon Hlds Stock (KDMN)